TL;DR
This Phase I clinical trial investigated oleclumab, a novel anti-CD73 antibody, as a monotherapy or in combination with durvalumab (an anti-PD-L1 antibody) in patients with advanced solid tumors. The study demonstrated a manageable safety profile and pharmacodynamic activity, showing that oleclumab can effectively target CD73 and potentially enhance anti-tumor immune responses, with some evidence of clinical activity observed in difficult-to-treat cancers.
What Problem Does This Paper Address?
Cancer cells often exploit the CD73 enzyme to create an immunosuppressive tumor microenvironment. CD73 converts AMP to adenosine, which then binds to purinergic receptors on immune cells, dampening anti-tumor immune responses. This creates a significant barrier for immunotherapies like checkpoint inhibitors, which rely on a robust immune system to fight cancer. This paper addresses the challenge of overcoming this adenosine-mediated immunosuppression by targeting CD73 directly with a novel antibody, oleclumab, and evaluating its safety and efficacy, both alone and in combination with a standard immunotherapy, durvalumab, in patients with advanced solid tumors.
Methods
This was a Phase I, multicenter, open-label, dose-escalation and dose-expansion study.
- Dose Escalation: Patients received escalating doses of oleclumab (5-40 mg/kg) either alone or in combination with durvalumab (10 mg/kg) intravenously every two weeks (Q2W). The primary objectives were to assess safety, tolerability, and determine the maximum tolerated dose (MTD).
- Dose Expansion: Patients with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or epidermal growth factor receptor-mutant non-small-cell lung cancer (EGFRm NSCLC) received oleclumab (40 mg/kg) in combination with durvalumab (10 mg/kg).
- Assessments: Safety was monitored through physical exams, lab tests, and adverse event grading. Tumor response was assessed using RECIST v1.1 criteria. Pharmacokinetic (PK) and immunogenicity (anti-drug antibodies, ADAs) were evaluated. Pharmacodynamic (PD) biomarkers, including CD73 expression and enzymatic activity in tumor tissue and peripheral blood, were analyzed.
Datasets
Not discussed in the paper. The study involved patient data collected during the clinical trial.
Key Insights and Ideas
- CD73 as a Viable Target: The study confirms that CD73 can be effectively targeted by a monoclonal antibody (oleclumab) in humans, leading to sustained decreases in free soluble CD73 and CD73 expression on peripheral T cells.
- Mechanism of Action in Humans: Pharmacodynamic studies showed that oleclumab not only reduces soluble CD73 but also decreases CD73 enzymatic activity in tumor tissue and reduces CD73 expression on tumor cells, supporting its intended mechanism of action.
- Potential for Immunomodulation: Evidence suggests oleclumab can lead to increased CD8+ T cell infiltration in tumors, a key indicator of enhanced anti-tumor immunity, particularly in immune-quiescent tumor types like MSS-CRC and PDAC.
- Combination Therapy Synergy: While monotherapy showed limited activity, the combination of oleclumab and durvalumab demonstrated some promising antitumor activity, especially in EGFRm NSCLC, suggesting a potential synergistic effect.
- Manageable Safety Profile: The combination therapy was generally well-tolerated, with no dose-limiting toxicities observed and common adverse events being manageable, reflecting the known safety profiles of both agents.
Key Results
- Safety: No dose-limiting toxicities (DLTs) were observed during dose escalation. Treatment-related adverse events (TRAEs) were common but generally manageable. The most frequent TRAEs across cohorts included fatigue, diarrhea, and rash. Grade 3-4 TRAEs were infrequent.
- Pharmacodynamics: Oleclumab treatment led to sustained decreases in free soluble CD73 and reduced CD73 expression on peripheral T cells. In tumor tissue, CD73 enzymatic activity decreased, and CD73+ tumor cells were reduced.
- Antitumor Activity:
- Dose Escalation: No objective responses (ORs) were observed.
- Expansion Cohorts: * MSS-CRC: Objective response rate (ORR) of 2.4% (1 complete response). 6-month progression-free survival (PFS) of 5.4%.
- PDAC: ORR of 4.8% (1 CR, 1 partial response). 6-month PFS of 13.2%.
- EGFRm NSCLC: ORR of 9.5% (4 partial responses). 6-month PFS of 16.0%.
- Biomarker Association: In patients with MSS-CRC and PDAC who achieved a confirmed response, ≥ 80% of tumor cells expressed CD73 at baseline, suggesting CD73 expression might be a predictive biomarker for response in these tumor types.
Limitations and Future Work
- Limited Sample Size: As a Phase I study, the sample size was relatively small, particularly in the dose-escalation cohorts, limiting definitive conclusions on efficacy.
- Exploratory Biomarker Analysis: While associations between baseline CD73 expression and response were observed in MSS-CRC and PDAC, the lack of association in EGFRm NSCLC, and the potential influence of prior treatments on archival samples, highlight the need for further validation of CD73 as a predictive biomarker.
- Tumor Microenvironment Complexity: Despite evidence of immunomodulation (increased CD8+ T cells), the lack of ORs in some patients with these changes underscores the complexity of the tumor microenvironment and the need for further understanding of immune cell quality and additional strategies to overcome immunosuppression.
- Future Directions: The paper suggests further evaluation of CD73 as a biomarker and ongoing studies utilizing oleclumab plus durvalumab or with standard chemotherapies in various tumor types, including NSCLC, CRC, and triple-negative breast cancer, to further explore its therapeutic potential.
Summary updated